2026-07-282 min
GHRH Analogues: Endpoint Hierarchy and Evidence Boundaries
An evidence-led GHRH Analogues review focused on endpoint hierarchy, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review TeamEditorial desk
Clinical Trial Review Team
Clinical Literature EditorsThe Clinical Trial Review Team summarizes study design, populations, endpoints and evidence limitations without turning research protocols into treatment advice.
47 published notesEvidence notes
Open
2026-07-281 min
Sermorelin vs Ipamorelin: GHRH and Ghrelin-Receptor Pathways Compared
A mechanism-first comparison of sermorelin and ipamorelin, with clear boundaries between signaling, human evidence and clinical claims.
Reviewed by Clinical Trial Review Team2026-07-272 min
GHRH Analogues: Population Generalizability and Evidence Boundaries
An evidence-led GHRH Analogues review focused on population generalizability, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-272 min
GHRH Analogues: Pharmacokinetic Interpretation and Evidence Boundaries
An evidence-led GHRH Analogues review focused on pharmacokinetic interpretation, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-262 min
GHRH Analogues: Receptor Pathway Map and Evidence Boundaries
An evidence-led GHRH Analogues review focused on receptor pathway map, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-252 min
Hexarelin: Healthy-Aging Claims and Evidence Boundaries
An evidence-led Hexarelin review focused on healthy-aging claims, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-252 min
Hexarelin: Sleep Claims and Evidence Boundaries
An evidence-led Hexarelin review focused on sleep claims, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-251 min
CJC-1295, Ipamorelin, Sermorelin and GHRP-6 Under the 2026 WADA List
An athlete-focused overview of CJC-1295, ipamorelin, sermorelin and GHRP-6 under the 2026 anti-doping framework.
Reviewed by Clinical Trial Review Team2026-07-242 min
Hexarelin: Body Composition Claims and Evidence Boundaries
An evidence-led Hexarelin review focused on body composition claims, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team